Grace A Kanzawa-Lee1, Robert Knoerl2, Clare Donohoe3, Celia M Bridges3, Ellen M Lavoie Smith3. 1. School of Nursing, University of Michigan, Ann Arbor, MI. Electronic address: gracekan@umich.edu. 2. Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, MA. 3. School of Nursing, University of Michigan, Ann Arbor, MI.
Abstract
OBJECTIVE: To describe the known predictors and pathophysiological mechanisms of chronic painful chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors and the challenges in assessing and managing it. DATA SOURCES: PubMed/Medline, CINAHL, Scopus, and PsycINFO. CONCLUSION: The research on chronic painful CIPN is limited. Additional research is needed to identify the predictors and pathophysiological mechanisms of chronic painful CIPN to inform the development of assessment tools and management options for this painful and possibly debilitating condition. IMPLICATIONS FOR NURSING PRACTICE: Recognition of the predictors of chronic painful CIPN and proactive CIPN assessment and palliative management are important steps in reducing its impact on physical function and quality of life.
OBJECTIVE: To describe the known predictors and pathophysiological mechanisms of chronic painful chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors and the challenges in assessing and managing it. DATA SOURCES: PubMed/Medline, CINAHL, Scopus, and PsycINFO. CONCLUSION: The research on chronic painful CIPN is limited. Additional research is needed to identify the predictors and pathophysiological mechanisms of chronic painful CIPN to inform the development of assessment tools and management options for this painful and possibly debilitating condition. IMPLICATIONS FOR NURSING PRACTICE: Recognition of the predictors of chronic painful CIPN and proactive CIPN assessment and palliative management are important steps in reducing its impact on physical function and quality of life.
Authors: Scott M Monfort; Xueliang Pan; Robyn Patrick; Janani Singaravelu; Charles L Loprinzi; Maryam B Lustberg; Ajit M W Chaudhari Journal: Gait Posture Date: 2016-06-14 Impact factor: 2.840
Authors: Ravi D Rao; Patrick J Flynn; Jeff A Sloan; Gilbert Y Wong; Paul Novotny; David B Johnson; Howard M Gross; Samer I Renno; Mohammed Nashawaty; Charles L Loprinzi Journal: Cancer Date: 2008-06-15 Impact factor: 6.860
Authors: F Streckmann; S Kneis; J A Leifert; F T Baumann; M Kleber; G Ihorst; L Herich; V Grüssinger; A Gollhofer; H Bertz Journal: Ann Oncol Date: 2014-02 Impact factor: 32.976
Authors: Deirdre R Pachman; Breanna L Weisbrod; Drew K Seisler; Debra L Barton; Kelliann C Fee-Schroeder; Thomas J Smith; Daniel H Lachance; Heshan Liu; Randy A Shelerud; Andrea L Cheville; Charles L Loprinzi Journal: Support Care Cancer Date: 2014-09-24 Impact factor: 3.603
Authors: Viktor R Drel; Pal Pacher; Igor Vareniuk; Ivan Pavlov; Olga Ilnytska; Valeriy V Lyzogubov; Jyoti Tibrewala; John T Groves; Irina G Obrosova Journal: Eur J Pharmacol Date: 2007-06-09 Impact factor: 4.432
Authors: Gregory D Leonard; Maurice A Wright; Mary G Quinn; Suzanne Fioravanti; Nancy Harold; Barbara Schuler; Rebecca R Thomas; Jean L Grem Journal: BMC Cancer Date: 2005-09-16 Impact factor: 4.430
Authors: Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Henry Schulz Journal: Oncol Res Treat Date: 2021-10-13 Impact factor: 2.825
Authors: Hester R Trompetter; Cynthia S Bonhof; Lonneke V van de Poll-Franse; Gerard Vreugdenhil; Floortje Mols Journal: Support Care Cancer Date: 2021-07-07 Impact factor: 3.603